Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, pharmacokinetics, immunogenicity and safety of wilate in children under 6 years with severe von Willebrand disease
2020-004344-28Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of von Willebrand factor concentrate in von Willebrand disease (VWD), sponsored by Octapharma. Primary endpoint: Total annualised bleeding rate (tABR) during prophylactic treatment. Started Jul 2022; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2020-004344-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004344-28.